IIT Gandhinagar Develops Hydrogel Technology to Simplify Colon Tumor Surgery

When I first read about the hydrogel breakthrough from IIT Gandhinagar, my initial thought wasn’t just about the science—it was about what Which means for communities grappling with colorectal cancer screening access right here in the United States. The news, breaking on April 25, 2026, detailed how researchers led by Harshil Dave developed an injectable gel with shear-thinning properties that creates a stable cushion beneath colon tumors during endoscopic procedures. Unlike saline solutions that dissipate quickly, this biocompatible polymer-based hydrogel maintains its position, allowing for more precise tumor lifting and removal while enabling targeted drug delivery with reduced systemic toxicity. It’s a development that could reshape outpatient endoscopic mucosal resection techniques, and as someone who’s followed medical technology adoption patterns for years, I immediately wondered how this might eventually ripple through healthcare systems in major metropolitan areas where colorectal cancer remains a leading cause of cancer-related deaths.

Given the global nature of this research announcement, I’ve chosen to focus on Chicago, Illinois—a city with significant colorectal cancer disparities and a dense network of academic medical centers actively involved in gastroenterology innovation. Chicago’s South and West sides, in particular, face higher incidence and mortality rates linked to delayed screening and treatment access, according to public health data from the Chicago Department of Public Health. While the IIT Gandhinagar hydrogel is still in pre-clinical stages, its potential to simplify polypectomy procedures could one day reduce procedure times, lower anesthesia risks, and improve outcomes in outpatient settings—factors that directly impact community health centers and ambulatory surgery centers across Chicagoland. The technology’s reliance on biocompatible polymers likewise aligns with broader trends in biomaterials research being pursued at institutions like Northwestern University’s Simpson Querrey Institute and the University of Illinois Chicago’s College of Engineering, where teams are exploring similar hydrogel applications for drug delivery and tissue engineering.

What makes this innovation particularly compelling from a public health standpoint is how it addresses two persistent challenges in colorectal cancer care: the technical difficulty of removing large or sessile polyps safely, and the require for localized therapies that minimize chemotherapy side effects. Current endoscopic techniques often rely on submucosal injection of solutions like saline or hyaluronic acid, which can fail to provide adequate lift in fibrotic lesions—a scenario that sometimes necessitates premature referral for surgery. The shear-thinning hydrogel described in the research circumvents this by transitioning to a fluid state under endoscopic pressure for easy injection, then rapidly re-gelling to maintain structural support. This property isn’t just a laboratory curiosity; it mirrors successful applications of shear-thinning materials in other medical devices, such as injectable fillers used in dermatology, suggesting a plausible pathway for adaptation. The hydrogel’s capacity for controlled, localized drug delivery could complement emerging immunotherapeutic approaches being studied at Chicago-based cancer centers like the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where researchers are investigating ways to combine surgical intervention with localized immune modulation.

The socio-economic implications are equally noteworthy. In a city like Chicago, where safety-net hospitals such as John H. Stroger Jr. Hospital of Cook County serve populations with limited access to specialized care, any technology that reduces procedure complexity and duration could help alleviate bottlenecks in endoscopy suites. Shorter, more reliable polypectomies mean more patients can be screened and treated efficiently—potentially increasing capacity in overburdened systems. If the hydrogel reduces the need for adjuvant systemic therapies through effective localized treatment, it could lower overall care costs and improve quality of life during recovery. These second-order effects matter immensely in a region where Medicaid coverage gaps and transportation barriers already hinder timely cancer care, particularly among Black and Latino communities disproportionately affected by late-stage diagnoses.

Looking ahead, the path from pre-clinical validation to clinical adoption will require rigorous testing through institutions equipped for gastrointestinal innovation. In Chicago, this could involve collaborative trials between the University of Chicago Medicine’s Digestive Diseases Center, Rush University Medical Center’s Department of Gastroenterology, and Advocate Health Care’s endoscopy networks—entities already engaged in multicenter studies on advanced polypectomy techniques. Regulatory pathways would likely involve the FDA’s gastrointestinal device division, with potential input from professional societies like the American Society for Gastrointestinal Endoscopy (ASGE), which has its headquarters in Oak Brook, Illinois, just outside the city. Success here wouldn’t just benefit Chicago; it could establish a model for how academic-industrial partnerships in the Midwest translate bench breakthroughs into community-ready tools, especially when guided by equity-focused implementation frameworks.

Given my background in biomedical technology trends, if this hydrogel advancement impacts you or someone you recognize in the Chicago area, here are the three types of local professionals you’ll want to connect with as this technology moves toward clinical utilize:

Gastroenterologists specializing in advanced polypectomy

Look for physicians affiliated with major academic medical centers (like UChicago Medicine or Northwestern) who actively participate in endoscopic innovation trials or publish techniques for complex polyp removal. Prioritize those with specific training in endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) and who discuss adopting new adjunctive agents during procedures—these clinicians will be earliest to evaluate and integrate novel submucosal agents like hydrogels once safety and efficacy data emerge.

Biomedical engineers focused on translational biomaterials

Seek professionals working in university-industry collaboration hubs such as the Illinois Innovation Network or the Polsky Center for Entrepreneurship at UChicago. Ideal candidates will have experience in hydrogel design, rheological testing (particularly shear-thinning behavior characterization), and preclinical safety modeling—expertise critical for adapting academic prototypes like the IIT Gandhinagar formulation to meet U.S. Manufacturing and sterilization standards.

Health equity coordinators in gastroenterology departments

Identify staff within hospital community health offices (e.g., at Sinai Chicago or Erie Family Health Centers) who specialize in expanding access to cancer screening for underserved populations. Their role will be vital in ensuring that any new technology doesn’t exacerbate existing disparities—instead, they can advocate for pilot programs in safety-net settings and help design outreach that informs communities about advances in minimally invasive polyp removal.

Ready to find trusted professionals? Browse our complete directory of top-rated experts in the Chicago, IL area today.